Johns Hopkins University: Majority of First-Wave COVID-19 Clinical Trials Have Significant Design Shortcomings, Study Finds
June 10, 2020
June 10, 2020
BALTIMORE, Maryland, June 10 -- Johns Hopkins University's Bloomberg School of Public Health issued the following news release:
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
The researchers, whose findings appear June 9 in the jour . . .
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
The researchers, whose findings appear June 9 in the jour . . .